HC Wainwright & Co. Downgrades Traws Pharma to Neutral, Announces $1 Price Target

Benzinga Newsdesk www.benzinga.com Negative 89.8%

Neg 89.8% Neu 0% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes downgrades Traws Pharma (NASDAQ:TRAW) from Buy to Neutral and announces $1 price target.